抗凝固薬の市場規模、シェア、成長分析：適応疾患別、投与経路別、薬剤クラス別、流通チャネル別、地域別 - 産業予測 2025～2032年

抗凝固薬市場規模は2023年に352億米ドルと評価され、2024年の392億1,000万米ドルから2032年には930億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは11.4％で成長する見通しです。

世界の抗凝固薬市場は、現代的なライフスタイルの変化に関連した重篤な心血管疾患の有病率の増加によって大きな成長を遂げています。高血圧、冠動脈性心疾患、高脂血症などの疾患が生命を脅かす疾患の増加に寄与しており、効果的な治療オプションへの需要が高まっています。抗凝固薬はこれらの疾患の管理に不可欠であり、脳卒中や心臓発作につながる危険な血栓を予防します。抗凝固治療、特にXareltoやEliquisのような新規経口抗凝固薬（NOACs）の技術革新は、イントロダクション以来高い商業的成功を収めています。しかし、同市場はジェネリック医薬品の普及や競合品の新規投入による課題に直面する可能性があります。米国の抗凝固薬市場は、血液希釈剤に対する継続的なニーズを反映し、予測期間中に持続的な成長が見込まれます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

抗凝固薬市場規模：適応疾患別& CAGR（2025-2032）

• 市場概要
• 肺塞栓症（PE）
• 深部静脈血栓症（DVT）
• 心房細動
• 心臓発作
• その他

抗凝固薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 注射

抗凝固薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• NOAC
  • エリキス
  • ベビクサ
  • ザレルト
  • サヴァイサとリクシアナ
  • プラダクサ
• ヘパリンとLMWH
• ビタミンK拮抗薬
• その他

抗凝固薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

抗凝固薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Johnson & Johnson（US）
• Bayer（Germany）
• Boehringer Ingelheim（Germany）
• Bristol-Myers Squibb（US）
• Daiichi Sankyo（Japan）
• Abbott Laboratories（US）
• Aspen Pharmacare（South Africa）
• Sanofi（France）
• Pfizer（US）
• Leo Pharma（Denmark）
• Dr. Reddy's Laboratories（India）
• GlaxoSmithKline（UK）
• AstraZeneca（UK）
• Novartis（Switzerland）
• Merck & Co.（US）
• Eli Lilly and Company（US）
• Amgen（US）
• Takeda Pharmaceutical（Japan）
• Roche（Switzerland）

結論と提言

Anticoagulants Market size was valued at USD 35.2 billion in 2023 and is poised to grow from USD 39.21 billion in 2024 to USD 93.01 billion by 2032, growing at a CAGR of 11.4% during the forecast period (2025-2032).

The global anticoagulants market is witnessing significant growth driven by the increasing prevalence of severe cardiovascular diseases linked to modern lifestyle changes. Conditions such as hypertension, coronary heart disease, and hyperlipidemia are contributing to a rise in life-threatening ailments, intensifying the demand for effective therapeutic options. Anticoagulant medications are essential in managing these diseases, preventing dangerous blood clots that can lead to strokes or heart attacks. Innovations in anticoagulant treatments, particularly with novel oral anticoagulants (NOACs) like Xarelto and Eliquis, have shown high commercial success since their introduction. However, the market may face challenges from the proliferation of generics and new competitor launches. The US anticoagulants market is poised for sustained growth in the forecast period, reflecting an ongoing need for blood thinners.

Top-down and bottom-up approaches were used to estimate and validate the size of the Anticoagulants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Anticoagulants Market Segments Analysis

Global Anticoagulants Market is segmented by Indication of disease, Administration Route, Drug Class, Distribution Channel and region. Based on Indication of disease, the market is segmented into Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks and Others. Based on Administration Route, the market is segmented into Oral and Injectable. Based on Drug Class, the market is segmented into NOACs, Heparin & LMWH, Vitamin K Antagonist and Others. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Anticoagulants Market

The increasing incidence of cardiovascular diseases, particularly atrial fibrillation and thromboembolic disorders, is a crucial factor fueling the expansion of the global anticoagulants market. As these health conditions continue to rise, so does the demand for efficient treatment options designed to prevent strokes and effectively manage related complications. This growing need for anticoagulants and various stroke management medications is driving market growth as healthcare providers seek effective therapies to address these pressing health issues. Consequently, the rising prevalence of such disorders is significantly influencing the dynamics of the anticoagulants market, highlighting the urgency for innovative medical solutions.

Restraints in the Anticoagulants Market

One of the primary challenges facing the anticoagulants market is the risk of blood-related complications associated with their use. The potential side effects of these medications, particularly in individuals with pre-existing conditions, often lead healthcare providers to hesitate in prescribing them. This apprehension may hinder the broader acceptance and utilization of anticoagulants in clinical settings, ultimately impeding market growth. As practitioners remain cautious, patient safety concerns can create a significant barrier to incorporating these essential drugs into treatment regimens. This issue underscores the need for enhanced awareness and education regarding the safe use of anticoagulants to promote their acceptance.

Market Trends of the Anticoagulants Market

The global anticoagulants market is witnessing a significant trend towards the adoption of personalized medicine, which seeks to tailor anticoagulant therapies based on individual patient profiles, including genetic factors and comorbidities. This shift aims to enhance therapeutic outcomes by optimizing drug selection and dosages to minimize adverse effects while maximizing efficacy. Such personalized approaches not only improve patient compliance but also foster better overall management of thromboembolic disorders. As healthcare providers increasingly embrace this customized treatment paradigm, the demand for innovative anticoagulation solutions is expected to rise, thereby shaping the future landscape of the anticoagulants market and driving growth through advanced therapeutic strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Anticoagulants Market Size by Indication of disease & CAGR (2025-2032)

• Market Overview
• Pulmonary Embolism (PE)
• Deep Vein Thrombosis (DVT)
• Atrial Fibrillation
• Heart Attacks
• Others

Global Anticoagulants Market Size by Administration Route & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Anticoagulants Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• NOACs
  • Eliquis
  • Bevyxxa
  • Xarelto
  • Savaysa & lixiana
  • Pradaxa
• Heparin & LMWH
• Vitamin K Antagonist
• Others

Global Anticoagulants Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacy
• Others

Global Anticoagulants Market Size & CAGR (2025-2032)

• North America (Indication of disease, Administration Route, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Indication of disease, Administration Route, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication of disease, Administration Route, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication of disease, Administration Route, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication of disease, Administration Route, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspen Pharmacare (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations